EFGR expression in patients with wild type KRAS mutation status: Avoiding unnecessary exposure to anti-EGFR therapies

Jaballah, A.

doi:10.26226/morressier.578f37fed462b8028d88f813

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] EGFR inhibitors have shown to have severe toxicities which can influence the patient's quality of life and may affect the decision to begin treatment with these medications. 7,8, [28][29][30][31][32][33][34][35][36][37] Inferior patient outcomes of EGFR inhibitor treatment in later lines might be an important determinant for the decision to choose a different chemotherapy to avoid the risk of these toxicities and potential treatment delays. It is also important for clinicians to have justifications for the use of EGFR inhibitors in later lines.…”

Section: Discussionmentioning

confidence: 99%

Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study

Johnson

Pham

Young

et al. 2022

kjm

View full text Add to dashboard Cite

Introduction. Colon cancer impacts the lives of Kansans and those across the United State.(1, 2) Epidermal growth factor receptor (EGFR) inhibitors, such as panitumumab and cetuximab, have gained popularity as first-line treatment for stage 4 colon cancer despite their toxicities.(3-5) EGFR inhibitors are an efficacious first-line treatment for stage 4 colon cancer, but no study has investigated outcomes comparing EGFR inhibitors as first-line treatment to it used as second- or third-line treatment. This study investigates EGFR inhibitor therapy estimated survival when used as first-, second-, and third-line. Methods. A retrospective review was done for patients with stage 4 colon cancer who underwent EGFR inhibitor treatment at a large academic center from November 2007 to August 2021. The patients were stratified into five groups by the line in which they received the EGFR inhibitor treatment. A log-rank test was used to analyze the groups, and the median survival for each group was determined. Results. A total of 68 patients were reviewed; 18 received first-line, 23 received second-line, 18 received third-line, 6 received fourth-line, and 3 received sixth-line treatment with an EGFR inhibitor. Fourth- and sixth-line therapies were excluded due to the small patient size. There was no significant difference in estimated survival time between any of the lines. Median survival of the therapies was found. Conclusions. There is no statistical difference in survival when EGFR inhibitors are used as first-, second-, or third-line for stage 4 colon cancer which should be considered when prescribing chemotherapy second- or third-line for this cancer.

show abstract